Spyre Therapeutics Files 8-K with Exhibits
Ticker: SYRE · Form: 8-K · Filed: Apr 13, 2026 · CIK: 0001636282
| Field | Detail |
|---|---|
| Company | Spyre Therapeutics, Inc. (SYRE) |
| Form Type | 8-K |
| Filed Date | Apr 13, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, filing, exhibits
TL;DR
Spyre Therapeutics dropped an 8-K, mostly exhibits. No major news, but check the filings.
AI Summary
On April 13, 2026, Spyre Therapeutics, Inc. filed an 8-K report detailing events under Regulation FD Disclosure and Other Events. The filing includes various exhibits, such as financial statements and data releases, but does not specify any new material agreements or financial figures.
Why It Matters
This filing indicates Spyre Therapeutics is providing updated information or disclosures to the public, which could be relevant for investors monitoring the company's activities.
Risk Assessment
Risk Level: low — The filing is primarily procedural and contains no new material financial information or significant corporate events.
Key Players & Entities
- Spyre Therapeutics, Inc. (company) — Filer of the 8-K report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events), along with providing financial statements and exhibits under Item 9.01.
What specific new information is disclosed in the 8-K filing regarding Spyre Therapeutics' business or financial condition?
The filing itself does not explicitly detail new business or financial information; it primarily consists of exhibits such as data releases and financial statements.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on April 13, 2026, at 07:46:49.
What types of documents are included as exhibits in this filing?
The exhibits include an iXBRL 8-K document, a data release (EX-99.1), and additional exhibits (EX-99.2) which appear to be graphical data or images.
Does this filing announce any new partnerships or acquisitions for Spyre Therapeutics?
The provided filing details do not explicitly mention any new partnerships or acquisitions; it focuses on Regulation FD disclosures and other events with accompanying exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 13, 2026 regarding Spyre Therapeutics, Inc. (SYRE).